Comparative Analysis of Oncotype DX Recurrence Scores in Screen‑Detected Versus Symptomatic Early‑Stage Breast Cancer: The COSSEB Study
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Screen-detected breast cancers (SDBCs) and symptomatic breast cancers (SBCs) show similar genomic risk scores (Oncotype DX Recurrence Score). Presentation mode should not solely guide adjuvant chemotherapy decisions for early breast cancer.
Area Of Science
- Oncology
- Genomics
- Breast Cancer Research
Background
- Screen-detected breast cancers (SDBCs) and symptomatic breast cancers (SBCs) often present with differing stage and biology.
- The 21-gene Oncotype DX Recurrence Score (ODX-RS) guides adjuvant treatment for ER-positive, HER2-negative early breast cancer.
- Investigating genomic risk differences based on breast cancer presentation mode is crucial for treatment decisions.
Purpose Of The Study
- To compare genomic risk, measured by ODX-RS, between SDBCs and SBCs.
- To evaluate if the mode of breast cancer presentation influences adjuvant treatment recommendations.
- To determine the impact of presentation mode on ODX-RS categories and subsequent treatment guidance.
Main Methods
- Retrospective analysis of 200 women (≥50 years) with ER-positive, HER2-negative early breast cancer.
- Cohort divided into 100 SDBCs and 100 age-matched SBCs with available ODX-RS testing.
- Comparison of clinicopathologic features, ODX-RS categories (≤25 vs. ≥26), and treatment recommendations between groups.
Main Results
- SDBCs were smaller and more frequently treated with breast-conserving surgery.
- Low HER2 expression was more common in SDBCs.
- ODX-RS distributions and adjuvant chemotherapy recommendations were largely similar between SDBCs and SBCs (19% vs. 23% recommended chemotherapy).
Conclusions
- Screen-detected and symptomatic ER-positive/HER2-negative early breast cancers exhibit comparable ODX-RS distributions.
- Presentation mode alone should not dictate adjuvant chemotherapy decisions; multigene testing is essential.
- Individualized treatment planning requires ODX-RS and standard clinicopathologic factors; further prospective studies are warranted.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
Related Concept Videos
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...